Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A global analysis of the value of precision medicine in oncology – The case of non-small cell lung cancer
Thomas Hofmarcher, Chiara Malmberg, Peter Lindgren
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 14

Showing 14 citing articles:

Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review
Juan Carlos Restrepo, Darly Martínez Guevara, Andrés Pareja López, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2338-2338
Open Access | Times Cited: 8
Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm
Nesrine Lajmi, Sofia Alves-Vasconcelos, Apostolos Tsiachristas, et al.
Cambridge Prisms Precision Medicine (2024) Vol. 2
Open Access | Times Cited: 6
Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non–Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02
Zhenhao Qi, Shinya Tokuhiro, Justin I. Odegaard, et al.
Journal of Molecular Diagnostics (2025) Vol. 27, Iss. 2, pp. 119-129
Closed Access
Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology
Astrid Kramer, Lucas Frederik van Schaik, Daan van den Broek, et al.
PharmacoEconomics (2025)
Open Access
The Cost Effectiveness of Genomic Medicine in Cancer Control: A Systematic Literature Review
Mackenzie Bourke, Aideen M. McInerney‐Leo, Julia Steinberg, et al.
Applied Health Economics and Health Policy (2025)
Open Access
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review
Razelle Kurzrock, Aadel A. Chaudhuri, David Feller‐Kopman, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 4, pp. 1217-1231
Open Access | Times Cited: 4
Lung cancer after the genomic turn: From the biopolitics of ‘lifestyle’ to the transcorporeality of breath
Jianni Tien, Katherine Kenny, Alex Broom
The Sociological Review (2024) Vol. 72, Iss. 6, pp. 1373-1392
Closed Access | Times Cited: 1
Decision: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R1/PR6
Nesrine Lajmi, Sofia Alves-Vasconcelos, Apostolos Tsiachristas, et al.
(2024)
Open Access
Recommendation: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R0/PR2
Nesrine Lajmi, Sofia Alves-Vasconcelos, Apostolos Tsiachristas, et al.
(2024)
Open Access
Recommendation: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R1/PR5
Nesrine Lajmi, Sofia Alves-Vasconcelos, Apostolos Tsiachristas, et al.
(2024)
Open Access
Decision: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R0/PR3
Nesrine Lajmi, Sofia Alves-Vasconcelos, Apostolos Tsiachristas, et al.
(2024)
Open Access
Health disparities among cancer patients who received molecular testing for biomarker-directed therapy
Elisabeth I. Heath, Gregory Dyson, Jennifer R. Ribeiro, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 10, pp. 2598-2609
Open Access
Author comment: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R1/PR4
Bass Hassan
(2024)
Open Access
Author comment: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R0/PR1
Bass Hassan
(2023)
Open Access
Page 1

Scroll to top